Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Innoviva (INVA) Long-Term Debt Repayments (2010 - 2012)

Innoviva posted quarterly Long-Term Debt Repayments of $13000.0 for Q2 2012, down 74.51% year-on-year from $51000.0 in Q3 2011, and down 76.79% on a QoQ basis from $56000.0 in Q1 2012.

Innoviva (INVA) has 3 years of Long-Term Debt Repayments data on file, last reported at $13000.0 in Q2 2012.

  • For the quarter ending Q2 2012, Long-Term Debt Repayments fell 74.51% year-over-year to $13000.0; the trailing twelve-month figure through Dec 2012 stood at $69000.0 (down 66.5% YoY), and the FY2012 full-year result was $69000.0, down 66.5% from the prior year.
  • Long-Term Debt Repayments for Q2 2012 stood at $13000.0, down from $56000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $62000.0 in Q1 2011 and bottomed at $13000.0 in Q2 2012.
  • The 3-year median for Long-Term Debt Repayments is $52000.0 (2011), against an average of $46250.0.
  • The widest annual swing landed in 2011, when Long-Term Debt Repayments grew 11.11%; it then tumbled 74.51% in 2012.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $36000.0 in 2010, then gained by 11.11% to $40000.0 in 2011, then sank by 67.5% to $13000.0 in 2012.
  • The last three Long-Term Debt Repayments figures came in at $13000.0 (Q2 2012), $56000.0 (Q1 2012), and $40000.0 (Q4 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2012 13,000.00
Jun 30, 2012 13,000.00
Mar 31, 2012 56,000.00
Mar 31, 2012 56,000.00
Dec 31, 2011 40,000.00
Dec 31, 2011 40,000.00
Sep 30, 2011 53,000.00
Sep 30, 2011 53,000.00
Jun 30, 2011 51,000.00
Jun 30, 2011 51,000.00
Mar 31, 2011 62,000.00
Mar 31, 2011 62,000.00
Dec 31, 2010 36,000.00
Dec 31, 2010 36,000.00
Sep 30, 2010 59,000.00
Sep 30, 2010 59,000.00